Habitual caffeine consumption moderates the antidepressant effect of dorsomedial intermittent theta-burst transcranial magnetic stimulation.
Adolescent
Adult
Caffeine
/ administration & dosage
Coffee
Combined Modality Therapy
Depressive Disorder
/ drug therapy
Double-Blind Method
Drinking Behavior
/ physiology
Energy Drinks
Female
Humans
Male
Middle Aged
Outcome Assessment, Health Care
Prefrontal Cortex
/ drug effects
Purinergic P1 Receptor Antagonists
/ administration & dosage
Transcranial Magnetic Stimulation
Young Adult
Adenosine
caffeine
coffee
depression
rTMS
repetitive transcranial magnetic stimulation
Journal
Journal of psychopharmacology (Oxford, England)
ISSN: 1461-7285
Titre abrégé: J Psychopharmacol
Pays: United States
ID NLM: 8907828
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
entrez:
7
12
2021
pubmed:
8
12
2021
medline:
22
2
2022
Statut:
ppublish
Résumé
Potentiating current antidepressant treatment is much needed. Based on animal studies, caffeine may augment the effects of currently available antidepressants. Here, we tested whether habitual caffeine consumption moderates the antidepressant effects of repetitive transcranial magnetic stimulation (rTMS) using intermittent theta-burst stimulation (iTBS). Forty patients with current depressive episodes were randomized to active iTBS ( Habitual caffeine consumption was associated with symptom improvement following active iTBS ( Habitual caffeine consumption moderated the antidepressant effect of dorsomedial iTBS, consistent with caffeine improving antidepressant pharmacological treatments in animals. Caffeine is an antagonist of adenosine receptors and may enhance antidepressant effects through downstream dopaminergic targets.
Sections du résumé
BACKGROUND
Potentiating current antidepressant treatment is much needed. Based on animal studies, caffeine may augment the effects of currently available antidepressants.
OBJECTIVE
Here, we tested whether habitual caffeine consumption moderates the antidepressant effects of repetitive transcranial magnetic stimulation (rTMS) using intermittent theta-burst stimulation (iTBS).
METHODS
Forty patients with current depressive episodes were randomized to active iTBS (
RESULTS
Habitual caffeine consumption was associated with symptom improvement following active iTBS (
CONCLUSION
Habitual caffeine consumption moderated the antidepressant effect of dorsomedial iTBS, consistent with caffeine improving antidepressant pharmacological treatments in animals. Caffeine is an antagonist of adenosine receptors and may enhance antidepressant effects through downstream dopaminergic targets.
Identifiants
pubmed: 34872405
doi: 10.1177/02698811211058975
pmc: PMC8652363
doi:
Substances chimiques
Coffee
0
Purinergic P1 Receptor Antagonists
0
Caffeine
3G6A5W338E
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1536-1541Références
Lancet. 2013 Nov 9;382(9904):1575-86
pubmed: 23993280
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Brain Stimul. 2020 Mar - Apr;13(2):337-340
pubmed: 31711880
Physiol Behav. 2013 Jan 17;109:1-7
pubmed: 23159724
Prog Neuropsychopharmacol Biol Psychiatry. 2015 Mar 3;57:117-31
pubmed: 25445063
J Am Diet Assoc. 2005 Jan;105(1):110-3
pubmed: 15635355
Acta Psychiatr Scand. 1994 Jan;89(1):21-8
pubmed: 8140903
Int Rev Neurobiol. 2005;63:191-270
pubmed: 15797469
Am J Psychiatry. 2006 Nov;163(11):1905-17
pubmed: 17074942
J Clin Psychiatry. 2013 Jul;74(7):e636-41
pubmed: 23945458
Front Pharmacol. 2018 Jun 01;9:526
pubmed: 29910727
Hum Psychopharmacol. 2009 Jan;24(1):29-34
pubmed: 19016251
Brain Stimul. 2018 Mar - Apr;11(2):426-434
pubmed: 29239776
Brain Stimul. 2013 May;6(3):231-40
pubmed: 22975030
JAMA Psychiatry. 2020 Dec 1;77(12):1286-1295
pubmed: 32725180
J Affect Disord. 2021 Jul 1;290:308-315
pubmed: 34020205
Biol Psychiatry. 2006 Jun 15;59(12):1151-9
pubmed: 16566899
Arch Gen Psychiatry. 2005 Apr;62(4):409-16
pubmed: 15809408
Proc Natl Acad Sci U S A. 2015 Jun 23;112(25):7833-8
pubmed: 26056314
Curr Pharm Des. 2008;14(15):1468-74
pubmed: 18537670
Compr Psychiatry. 2013 Jul;54(5):568-74
pubmed: 23351831
Int Rev Neurobiol. 2014;119:373-93
pubmed: 25175973
Arch Intern Med. 2011 Sep 26;171(17):1571-8
pubmed: 21949167
Annu Rev Psychol. 1989;40:191-225
pubmed: 2648975
Front Psychiatry. 2014 Jun 13;5:67
pubmed: 24982640
Fed Pract. 2015 Apr;32(Suppl 3):30S-37S
pubmed: 30766117
J ECT. 2018 Dec;34(4):233-239
pubmed: 29768288
J Psychiatry Neurosci. 2019 Feb 05;44(3):151-163
pubmed: 30720259
Biol Psychiatry Cogn Neurosci Neuroimaging. 2017 Oct;2(7):556-565
pubmed: 29560909
J Neurosci. 2011 Jul 6;31(27):10067-75
pubmed: 21734299
Naunyn Schmiedebergs Arch Pharmacol. 2016 Feb;389(2):211-21
pubmed: 26614569
J Neural Transm (Vienna). 2015 Sep;122(9):1253-61
pubmed: 25663170
Pharmacol Rev. 2018 Apr;70(2):384-411
pubmed: 29514871
Eur Addict Res. 2005;11(1):22-31
pubmed: 15608468
Lancet. 2018 Apr 28;391(10131):1683-1692
pubmed: 29726344
Int J Methods Psychiatr Res. 2012 Sep;21(3):169-84
pubmed: 22865617
Am J Psychiatry. 2020 Aug 1;177(8):716-726
pubmed: 32252538
Br J Pharmacol. 2001 Sep;134(1):68-77
pubmed: 11522598
Brain Behav. 2019 May;9(5):e01275
pubmed: 30941915